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of cases, a smoking in 35.83% of cases, 17.25% of obesity cases, hyper-
cholesterolemia in 45% of cases.
The coronarography was performed in 69% of cases for acute coronary
syndrome, assessment of stable angina in 32% of cases. Two-vessel coronary
artery disease was noted in 20% of patients and Three-vessel disease repre-
sented 35% of cases.
Drug-eluting stents were used in 60% of cases, 10% of coronary artery
bypass graft. We noted six deaths, including 2 postoperative.
Conclusion: Coronary artery disease is not only more frequent in dia-
betics; it is also more severe because of the spread and complexity of coronary
lesions, with higher rates of thrombosis and restenosis of stents.
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Background: The prevalence of metabolic syndrome is correlated with the
extent of damage in symptomatic cardiovascular disease
The aim of our study was to evaluate the impact of metabolic syndrome on
morbidity and in-hospital mortality, particularly in terms of death and severe
heart failure, and analyze the relative importance of different components that
define the metabolic syndrome on the occurrence of these events.
Methods and results: The study included 409 patients admitted for myo-
cardial infarction. The average age of our patients was 64, 42, with a male pre-
dominance. Fifty percent patients were hypertensive, 46% had type 2 diabetes,
twenty percent of patients had hypertriglyceridemia and 45% a hypoHDLemia.
Thirty percent patients have a positive microalbuminuria, 60% have a chronic
smoking. The prevalence of metabolic syndrome was 45% defined by the com-
bination of at least three risk factors from the definition of the IDF (Interna-
tional Diabetes Federation) on 2005. Nineteen percent patients had a history of
myocardial infarction and 47% had heart failure. The death during hospitaliza-
tion were 10%. The history of stroke were present in 10% of cases.
Conclusion: The patient who have a metabolic syndrome are at high car-
diovascular risk and represent a strong signal that must be detected, managed
and fight against all the factors that compose it.
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Introduction: Left ventricular aneurysm (LVA) constitutes an important
complication of acute transmural myocardial infarction (MI). Angiographically
defined, LVA has been reported in 7.6% of patients with coronary artery disease
(CAD) referred for coronary angiography. It is well established that patients
with LVA are exposed to a higher incidence of complications such as arrhyth-
mias, thromboembolic phenomena, and congestive heart failure.
Case report: We report the case of a 76-year-old woman, hypertensive,
diabetic, with a history of percutaneous coronary angioplasty with stenting
of the distal and mid segments of left anterior descending artery (LAD) for
myocardial infarction 10 months ago, admitted to our cardiology department
for acute coronary syndrome without ST-segment elevation complicated by
left ventricular failure. The electrocardiogram showed sinus rhythm at 100 beats
per minute with abnormal Q waves (sequelae of necrosis) in the inferior
leads. Transthoracic and transesophageal echocardiography revealed an
aneurysm of the infero-basal left ventricular wall, having implantation base
in the small mitral valve, measuring 44 mm x 44 mm and filled by a
thrombus. The LV was dilated and hypertrophied with a reduced ejection
fraction (EF) of 40%. There was a severe ischemic mitral regurgitation
(MR). MRI confirmed the ultrasound findings. The coronary angiography
objective diffuse coronary restenosis in the stent of the LAD and an occlu-
sion of the distal right coronary artery, not supplied by the left coronary
arteries. The indication for surgery was taken. The patient underwent a
coronary artery bypass grafting of LAD, a mitral valve repair by Carpentier
ring and a resection of the ventricular aneurysm. Her postoperative course
was uneventful. The postoperative echocardiographic control showed an
improvement of LVEF to 50%, a minimal MR.
Conclusion: The left ventricular aneurysm, late mechanical complication
of myocardial infarction, presents a management problem. Surgical treatment
is usually effective and followed by a marked improvement in function but is
burdened with a heavy postoperative mortality.
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Aims: Non compliance to dual antiplatelet therapy (DAT) after PCI is
associated to a higher cardiovascular mortality. Previous studies about DAT
discontinuation only analysed non compliance during short periods, generally
less than three months. The purpose of this monocentric prospective study was
to analyse DAT discontinuation during a one year follow-up in real-life
patients after PCI.
Method and results: We prospectively included 103 consecutive patients
who underwent PCI. They underwent a phone questionnaire focusing on DAT
compliance every three months on a one year follow-up. Three groups of patients
were defined according to compliance WHO (World Health Organization) defi-
nition: DAT oversight more than once a week, self-willed DAT discontinuation
and good adherers. A total of 100 patients had complete data. Global non com-
pliance to DAT (oversight and discontinuation) was about 33% at twelve months.
Twenty seven percent patients forgot DAT more than once a week at one year.
More than 50% of DAT oversight occurred within the first month. Self-willed
DAT discontinuation occurred in 13% cases, with a progressive increase on the
first 12 months, mainly explained by weariness or treatment side effects.
Conclusion: Global DAT non compliance at one year was about 33%
cases. There were two profiles of DAT non compliance: oversight, occurring
almost within the first month and self-willed DAT discontinuation which pro-
gressively increased during the first year. Therapeutic education seems to be
pivotal to prevent both behaviours.
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Myocardial ischemia during acute coronary syndromes (ACS) without ST
segment elevation is responsible for diastolic dysfunction. The aim of our
study is to evaluate LVFP in patients suffering from an ACS without ST seg-
ment elevation and to appreciate the additive prognostic value of this param-
eter beside the Global Registry of Acute Coronary Events (GRACE) score and
the left ventricular ejection fraction (LVEF). This strategy may lead to a better
risk stratification in this population.
Methods: We performed a prospective study in 220 patients admitted to
our coronary care unit for ACS without ST segment elevation from January
2007 to September 2008. Risk score stratification using the GRACE score and
assessment of systolic and diastolic functions by echocardiography was per-
formed in all patients. LVFP was estimated by the E/e’ ratio and the differ-
ence between Ap and Am.
Results: The mean age was 58 years with a sex ratio of 4.3. Hypertension,
diabetes and dyslipidemia were present in 45%, 45% and 32.2% of cases respec-
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tively. The mean body-mass index was 26.1 kg/m².In-hospital mortality was
1.84%. After 2-years follow up, the survival rate was 92.16% with an event-free
survival rate of 71.9%. In our population, elevated LVFP was found in 32.3%
of cases mainly in elderly (p=0.007), diabetic (p=0.041), patients with hyperten-
sion (p<0.001), with a history of myocardial infarction (p<0.001) and in Killip
3 or 4 class (p<0.001). Chronic kidney disease and anemia were also found pre-
dictive of elevated LVFP (p values of 0.007 and 0.016 respectively). An inter-
mediate or high GRACE score and LVEF< 45% are predictive of poor
prognosis. The additive prognostic value of LVFP was calculated and confirmed
in our study. In fact E/e’ ratio>15 improve the prognostic value of the combina-
tion of the GRACE score and LVEF with a chi² value of 54.74.
Conclusion: Our study confirms the additive prognostic value of LVFP in
addition to the GRACE risk score and LVEF in patients admitted for ACS
without ST segment elevation.
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Background: Although silent Atrial Fibrillation (AF) has been suggested
to be common in Acute myocardial infarction (AMI), the true incidence and
characteristics of silent AF in AMI remains unknown. We aim to assess silent
AF incidence and determinants, including left atrium parameters.
Methods and results: 581 consecutive AMI were prospectively analyzed
by Continuous ECG Scope Monitoring (CSM) for 48H after hospital admis-
sion. New onset AF was defined as at least 1 episode >30 sec, absence of
p waves, and irregular RR intervals on CSM or absence of p waves or irreg-
ular RR intervals on 12-lead ECG, without any duration criterion. Left Atrial
(LA) dimensions and Left Ventricular Ejection Fraction (LVEF) were deter-
mined on admission by echocardiography. We analyzed the study population
into 3 groups: No AF, silent AF (defined as asymptomatic episodes of AF
lasting at least >30 sec) and symptomatic AF (defined as symptomatic epi-
sodes of AF that lasted ≥12hours). Ninety-five (16.4%) patients had AF on
CSM, of whom 76 (80%) developed silent AF. Compared with No AF group,
patients with silent AF were older (80 vs 62 y; p<0.001), more frequently
women (45 vs 27%; p=0.006), hypertensive (76% vs 52%; p<0.001) but less
smoker (18% vs 38%; p<0.001). Moreover, they had significant LA enlarge-
ment based on indexed LA diameter (24.4 vs 20.3 mm/m²; p<0.001), and
indexed left atrial volume (LAVI) (36.12 vs 26.95 ml/ m²; p=0.002). They also
had impaired LVEF (46 vs 54%; p<0.001). By multivariate analysis, age (OR
(95%CI): 1.06 (1.03-1.09), CRP (OR (95%CI): 1.01( 1.00-1.02) and indexed
LA diameter (OR (95%CI): 2.37 (1.31-4.25) were predictors of silent AF. By
ROC curve analysis, LAVI at 26.88 ml/m² was the best cutoff value to predict
silent AF occurrence after AMI, with sensibility at 73% and specificity at 50%.
Conclusion: In this prospective study in routine clinical practice, silent AF
in AMI is very common and is mostly underdiagnosed by classical discon-
tinued serial ECG monitoring. Left atrial parameters assessed by echocardiog-
raphy, including indexed diameter and LAVI, should be evaluated on
admission to predict silent AF occurrence.
056
Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation
myocardial infarction
Laurent Bonello (1), Marc Laine (1), Elise Camilleri (2), Sebastien
Arméro (1), Julie Berbis (3), Paul Barragan (4), Franck Paganelli (1),
Francoise Dignat-Geoge (5), Laurence Camoin-Jau (5)
(1) Hôpital ord, cardiologie, Marseille, France – (2) Hôpital de Marti-
gues, Martigues, France – (3) Faculté de médecine de Marseille, Mar-
seille, France – (4) Clinique les Fleurs, Ollioules, France – (5) Hôpital de
la Conception, Marseille, France
Background: Optimal platelet reactivity (PR) inhibition is critical to pre-
vent thrombotic events in primary percutaneous coronary intervention (PCI).
We aimed to determine the relationship between high on-treatment platelet
reactivity (HTPR) and ST-elevation myocardial infarction (STEMI) following
a 600mg loading dose (LD) of clopidogrel.
Methods and results: We performed a prospective monocentre study
enrolling patients on clopidogrel undergoing PCI. The VASP index was used
to assess PR inhibition after clopidogrel LD. HTPR was defined according to
the consensus as a VASP index ≥50%. The present study included 833 patients
undergoing PCI. Most patients had PCI for an acute coronary syndrome
(58.7%). The mean VASP index was 50 ±23% with a large inter-individual
variability (range: 1-94%). Patients with a VASP index ≥50% were signifi-
cantly older (p= 0.03), with a higher BMI (p<0.001), more often diabetic
(p=0.03), taking omeprazole (p=0.03), admitted for an ACS and with a high
fibrinogen level compared to good responders (VASP<50%). In multivariate
analysis BMI, omeprazole use, acute coronary syndrome and high fibrinogen
level (p<0.001) remained significantly associated with HTPR. Of importance,
in this analysis STEMI was independently associated with HTPR when com-
pared with the other forms of ACS (NSTEMI and unstable angina) with an
odd ratio of 2.14 (95% CI: 1.3 –3.5; p=0.003). 
Conclusion: STEMI is associated with high on-treatment platelet reactivity
following 600 mg of clopidogrel. The present results suggest that 600 mg of
clopidogrel may not be able to achieve an optimal PR inhibition in STEMI
patients undergoing PCI and more potent drugs may be preferred.
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Objective: Benefits of statins in the long term follow-up of ST elevation
myocardial infarction (STEMI) have been established, but the short term ben-
efits of early statins prescription remain unproven, especially according to the
reperfusion result.
Aim of the study: to assess the benefit of early statins prescription in in-
hospital outcome of STEMI patients.
Methods: Between January 1995 and November 2011, 1388 patients
admitted for STEMI have been included in the MIRAMI (MonastIR Acute
Myocardial Infarction) registry. During this period, statins were introduced in
early management of STEMI patients. This enabled us subdivide patients,
after excluding those with missing treatment data, into 2 groups: early pre-
scribed statins group (n= 561) versus no statins prescribed group (n=804). We
compared in-hospital outcome between these two groups and among the sub-
groups of successful or failure reperfusion therapy.
Results: In the early statins prescription group, there was a significant
reduction of in-hospital mortality (12.1% vs 5.3%, p<0.001), ventricular
arrhythmias (5.3% vs 2.2%, p<0.001 for ventricular tachycardia, 5.6% vs
3.1%, p=0.03 for ventricular fibrillation), and atrial fibrillation (7.7% vs 5%,
p=0.049). When successful reperfusion (whatever the method is), mortality
was lower in the early statins prescription group (6.8% vs 1.8%, p=0.001).
This difference is less pronounced when reperfusion fails (16.1% vs 11%,
p=0.07).
Conclusion: Early statins prescription improves in-hospital outcome (mor-
tality, ventricular and supra-ventricular arrhythmias). This improvement is
much marked when reperfusion is successful with only a trend to beneficial
effect in case of reperfusion failure.
